Methoxyflurane delivered via a hand-held inhaler is a proven analgesic which has been used in Australasia for emergency relief of trauma associated pain since the 1970s. The agent is self-administered by the patient under the supervision of trained personnel. More than 5 million patients have received inhaled methoxyflurane without significant side effects. Methoxyflurane is also licensed in Australasia for the relief of pain in monitored conscious patients requiring analgesia for minor surgical procedures. Recent clinical studies undertaken in a variety of outpatient settings, including colonoscopy, prostate biopsy, dental procedures, bone marrow biopsy, and the management of burns dressings, indicate that inhaled methoxyflurane has significant analgesic activity, without producing deep sedation or respiratory depression. Return to full psychomotor activity is rapid. Thus, methoxyflurane may be a suitable and well-tolerated alternative to traditional i.v. sedative agents for outpatient medical and surgical procedures. There are direct advantages to the patient in terms of rapid recovery and an early return to normal activities, and significant benefits for outpatient departments in terms of cost saving and rate of throughput. Further randomised controlled trials comparing the efficacy, safety, and cost-effectiveness of inhaled methoxyflurane against traditional i.v. sedative techniques are currently in progress.
Editor's key points
Small-scale studies have demonstrated that methoxyflurane self-administration can provide satisfactory analgesia for various procedures, avoiding the risks of deep sedation. Administration brings psychomotor impairment, which resolves rapidly on stopping inhalation, with rapid return to full fitness. Further studies, including large randomised controlled trials, are required. The authors suggest that these are likely to add to the evidence supporting more widespread use of this agent.
Historical perspective: methoxyflurane as an anaesthetic agent
Interest in fluorinated hydrocarbons and ethers as anaesthetic agents began in the 1940s. 1 Extensive testing by the pharmaceutical industry on several potential agents led to the introduction of halothane (Ayerst Laboratories, New York, USA) and methoxyflurane (Abbott Laboratories, Montreal, Canada) as volatile anaesthetics for general anaesthesia in 1960. Artusio and colleagues, 2 Van Poznak and colleagues, 3 and Millar and Morris 4 investigated the anaesthetic and physiological properties of methoxyflurane. This agent was found to have significant benefits over other volatile anaesthetics available at the time. In particular, cardiovascular stability was maintained under methoxyflurane anaesthesia and the dysrhythmias commonly noted with halothane were absent. This was a particular benefit in operations where adrenaline was required to be used as part of an infiltration local anaesthesic (LA) technique, or in sick patients who already exhibited high levels of catecholamine secretion secondary to the stress response. 4, 5 Of specific relevance to this review, the profound analgesic properties of methoxyflurane, which extended well into the postoperative period, were recognised early on. 6, 7 Many clinical studies conducted during the early 1960s suggested improved safety of methoxyflurane over halothane in a wide variety of clinical anaesthetic settings, and thousands of general anaesthetics were performed using this agent. 5, 8 However, in the mid-1960s, concerns over the renal toxicity of methoxyflurane began to emerge. 9 Two significant case series described an unusual form of high output acute renal failure correlated with the intraoperative use of methoxyflurane as a general anaesthetic. 10, 11 The clinical manifestations included excessive diuresis, thirst, and severe hypernatraemia resistant to vasopressin administration, indicating impaired renal tubular concentrating ability. 9 The vast majority of these patients recovered full renal function within a relatively short space of time, with most recorded deaths being related to complications of the primary surgical pathology. 9 Nevertheless, the need to manage fluid balance in the presence of high output renal failure led to prolonged hospital admission and the patients' stay in hospital was a significant contributing factor to poor long-term outcome in some cases. 9 The exact cause of the renal tubular dysfunction has never been established. Although methoxyflurane is a fluorinated ether, other volatile agents inducing higher serum concentrations of inorganic fluoride do not produce high output renal failure. 12 A metabolic pathway unique to methoxyflurane, resulting in the production of other potentially nephrotoxic agents acting in tandem with inorganic fluoride to inhibit tubular reabsorption, has been postulated, but never directly proven. 9, 13 Postoperative renal tubular dysfunction has only been observed in a retrospective setting where long duration inhalational anaesthesia resulted in high cumulative doses of methoxyflurane.
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Nevertheless, methoxyflurane was withdrawn from North American clinical anaesthetic practice in the late 1970s, and fell into gradual disuse globally as an anaesthetic agent over the next 10 years, as newer volatile agents with more rapid onset and offset became available.
Low-dose inhaled methoxyflurane as a potent short-term analgesic for emergency trauma pain Although methoxyflurane has been withdrawn for use as an anaesthetic agent, low-dose methoxyflurane delivered via a hand-held inhaler has been used by the Australian emergency services for the short-term relief of acute trauma pain since the early 1970s. Clinical trials have confirmed that this agent provides effective pain relief in acute trauma with no evidence of either renal or hepatic toxicity. 17, 18 The portability, safety profile, and rapid onset of analgesia means that this formulation of methoxyflurane is a very common type of pain relief given by Australian paramedics, 19, 20 and more than 5 million doses of inhaled methoxyflurane have been used in trauma patients with no significant adverse events reported. 21 Recent studies have confirmed the cardiovascular and respiratory stability of this agent in the pre-hospital setting, not only for trauma pain, but also for acute visceral pain.
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In the last few years, attention has focussed on whether methoxyflurane delivered via a hand-held inhaler can provide high quality, well-tolerated analgesia for a variety of outpatient procedures which would otherwise require i.v. sedation and analgesic techniques. 23 In addition, recent clinical studies have suggested that methoxyflurane has an anxiolytic effect, 23, 24 and these combined properties of potent analgesia and reduced anxiety may make methoxyflurane a suitable and well-tolerated alternative to i.v. sedative agents.
Dosage and administration of inhaled methoxyflurane
The physical and chemical properties of methoxyflurane are central to its efficacy as an analgesic for short medical and surgical outpatient procedures. It is a highly lipid soluble volatile liquid with a high blood:gas partition coefficient. 21 The minimum alveolar concentration of 0.2% suggests potent anaesthetic activity. However, in practice, the high lipid solubility and low vapour pressure of methoxyflurane means that the onset of sedation is very slow and thus, inhalation of small doses over a short period limits the sedative effect of this agent. 25 Methoxyflurane is currently presented in liquid form in a 3 ml vial, which is poured into a hand-held inhaler (Penthrox ® inhaler or 'green whistle', Medical Developments International, Victoria, Australia). The liquid is absorbed onto a wick and the patient inhales vaporised methoxyflurane via a mouthpiece. The inhaler has a dilutor hole which entrains air during inhalation, so that the concentration of agent delivered is either 0.2e0.4% when the dilutor hole is uncovered or 0.5e0.7% when the patient closes the dilutor hole with a finger. Analgesia is usually felt within a few breaths. The maximum recommended dose of methoxyflurane in a 24-h period is 6 ml (two vials). 5 Either one or two vials of methoxyflurane are sufficient for the majority of outpatient procedures; with continuous use one vial can provide analgesia for up to 20e25 min, but more commonly with surgical procedures, use is intermittent which extends the period of analgesia. The option of adding a second vial further extends the period of analgesia (50e55 min when inhaled continuously). 23, 26 The total weekly maximum dose is currently 15 ml, and it is recommended that inhaled methoxyflurane should not be given on consecutive days.
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Safety of methoxyflurane as a selfadministered, low-dose inhalational analgesic for procedural pain
General overview
Although methoxyflurane is a volatile anaesthetic agent that may have the potential to trigger malignant hyperthermia (MH), there has been only one incident of MH after administration of methoxyflurane recorded on the Therapeutic Goods Administration (TGA, Department of Health, Australia) website (2000) . In this case, the agent was given in addition to other potent inducers of MH including succinylcholine and sevoflurane. 27 Nevertheless, methoxyflurane in any form is contraindicated in susceptible patients. 28 Minor adverse events such as nausea, dizziness, and somnolence are occasionally reported in the period immediately after the administration of inhaled methoxyflurane, 29 but these are usually brief and self-limiting. Low-dose methoxyflurane has no effect on myocardial contractility, and whilst bradycardia may occur, there are no reported episodes of significant cardiovascular instability associated with its use. 29 Although renal toxicity is extremely rare, use of inhaled methoxyflurane is contraindicated in patients with renal impairment, and caution is advised in diabetics and elderly patients. 29 However, in general, the available evidence suggests that when methoxyflurane is delivered via a hand-held inhaler, doses are small and of sufficiently short duration to avoid renal toxicity.
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With regard to occupational exposure, methoxyflurane levels in areas where the analgesic inhaler is regularly administered appear to be very low, suggesting minimal risk for healthcare workers in ambulances and hospital treatment rooms. 28 Modern risk assessment techniques derived a maximum exposure limit (MEL) of 15 ppm for methoxyflurane. Occupational exposures estimates are well below the proposed MEL. 30 Methoxyflurane is not flammable at the ambient temperatures usually encountered in hospital settings. 29 
Renal toxicity
The occurrence of high output acute renal failure after highdose methoxyflurane anaesthesia caused the withdrawal of this agent from anaesthetic practice in the mid-1970s. Measurement of end-tidal volatile agent was not possible in the decade when this phenomenon was described, nor could depth of anaesthesia be determined. Deep anaesthesia was often used rather than the very long-acting neuromuscular blocking agent available at the time (pancuronium) to obtain suitable conditions for abdominal surgery, so it is likely that methoxyflurane was frequently administered in high unregulated volumes for a prolonged time. In contrast, the Penthrox ® inhaler delivers a low 3 ml dose of methoxyflurane and is given over a very short period on time (i.e. minutes rather than hours), resulting in serum fluoride levels that have not been associated with renal tubular toxicity. 33 Several of the studies quoted here looked specifically for clinical and biochemical markers of methoxyflurane-induced renal dysfunction in their study populations and found no evidence of renal toxicity when the agent was used as a short-term lowdose analgesic for procedural pain. 15,17,18,23,24,34e36 Hepatotoxicity Liver toxicity is very rarely reported during methoxyflurane use as either an anaesthetic or an analgesic, 31 and is likely to be an idiosyncratic response as is occasionally seen with other volatile anaesthetic agents. For example, a presumed idiosyncratic response was described in a young woman who had received methoxyflurane via an inhaler during a series of three varicose vein sclerosing procedures several weeks apart. 37 Only one 3 ml dose of methoxyflurane was administered on each occasion. Clinical and biochemical indicators of acute hepatitis appeared immediately following the second procedure, and intensified after the third administration of inhaled methoxyflurane 1e2 weeks later. The patient developed mild jaundice and a liver biopsy revealed acute hepatitis. Clinical markers resolved spontaneously over the course of 8 days. No other cause for the liver pathology was found and an idiosyncratic response to methoxyflurane was diagnosed. 31 Since this case, methoxyflurane has been implicated as a cause of deranged liver function in two further patients, as reported to the TGA database in Australia. 27 Further details about these incidents are not currently available.
Clinical studies of the efficacy of inhaled methoxyflurane (Penthrox ® ) in medical and surgical procedures
Colonoscopy
Colonoscopy is one of the most commonly performed outpatient procedures in high-income societies, partly because of an increased awareness of early signs of bowel cancer and government-driven bowel-screening initiatives. However, significant numbers of colonoscopy patients are obese and have additional associated risk factors, including obstructive sleep apnoea. 38 Respiratory depression and airway obstruction are a significant hazard and the presence of an anaesthetist is increasingly required, placing a significant burden on hospital costs. 39 Nguyen and colleagues 23, 24 have investigated whether inhaled methoxyflurane via a proprietary inhaler might be a suitable and well-tolerated alternative to current i.v. sedation techniques for colonoscopy. In an initial prospective, multicentre randomised controlled trial, 23 patients underwent colonoscopy using an i.v. sedative technique (a standardised bolus of fentanyl and midazolam, followed by further small boluses of either agent as required), or analgesia delivered via a methoxyflurane inhaler, with the patients allowed to selfadminister as required up to a total dose of 6 ml. There were no significant differences in procedural times or polypectomy success rates between the two analgesic techniques, and pain scores, assessed via standard visual analogue scoring (VAS), were similar. Anxiety levels were measured using the StateTrait Anxiety Inventory Form Y. Anxiety scores were broadly similar across the two groups, although the specific sensation of 'nervousness' was lower in the methoxyflurane group. In those patients who had i.v. sedation, the mean fentanyl dose was 83.6 mg, and the mean dose of midazolam was 3.4 mg, indicating that additional sedation was required during the procedure. In contrast, all patients receiving methoxyflurane required only one dose of the inhaler at the start of the colonoscopy. Overall, patients using methoxyflurane felt more awake at an earlier time than patients receiving i.v. sedation, had a shorter time to oral intake, and were ready for discharge significantly earlier. A small number of patients using the inhaler (8% of the methoxyflurane group) required additional i.v. sedation, although this group exhibited higher levels of anxiety before the procedure, as assessed by both the patients themselves and the clinicians undertaking the colonoscopy. Significant adverse events, specifically hypotension and respiratory depression, appeared to be similar between the two groups. However, episodes of respiratory depression in the methoxyflurane group only occurred in those patients who had required additional i.v. sedation. A 30-day follow-up showed no instances of renal or hepatic toxicity associated with the use of methoxyflurane analgesia. In a further study, Nguyen and colleagues 24 studied the efficacy of inhaled methoxyflurane for colonoscopy in morbidly obese patients, who are at the highest risk of serious adverse events during this procedure performed under standard sedative techniques. One hundred and forty patients were recruited to the study, and were given the choice of either a standard i.v. sedation regime or selfadministered inhaled methoxyflurane for their colonoscopy. The alternative i.v. technique, termed Anaesthesia Assisted Deep Sedation (AADS), was performed as an initial bolus of a short-acting opioid plus midazolam, followed by propofol administered as either intermittent boluses or by continuous infusion. Patients undergoing AADS were given i.v. fluids and supplemental oxygen, whereas patients inhaling methoxyflurane were not. The colonoscopic procedure was carried out equally successfully in both groups, but the overall length of the procedure was significantly shorter in the methoxyflurane group. Although there was no difference between the satisfaction or anxiety scores of the two groups and higher pain scores during colonoscopy were reported with methoxyflurane [3.6 (0.2) vs 0.9 (0.1); P<0.001], pain was perceived as tolerable and short-lasting. Consequently, 28 of 34 methoxyflurane patients (82%) who had undergone a previous colonoscopy with AADS preferred methoxyflurane over AADS, whilst 90% were willing to receive methoxyflurane again for colonoscopy. Serious adverse events (hypotension, hypoxia, and dysrhythmias) occurred almost exclusively in the AADS group, who had an overall adverse event rate of 56%, as opposed to those in the methoxyflurane group where the total adverse event rate was 2%. As in the previous study, patients undergoing colonoscopic procedures with methoxyflurane had a significantly shortened time to first oral intake and time to discharge. Thirty-day follow-up of the methoxyflurane group showed no clinical or biochemical markers of renal or hepatic toxicity. The shorter procedure time, absence of serious adverse events, and earlier readiness for discharge led the authors to conclude that selfadministered methoxyflurane is a well-tolerated alternative for colonoscopy, even in high risk patients. There is a rapid return (within 30 min of ceasing administration) to normal psychomotor activity. 40 Significant cost savings have been identified, as well as the potential to reduce waiting list times for this common procedure.
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Bone marrow biopsy
The only double-blind, randomised trial of methoxyflurane vs placebo in conjunction with local anaesthetic reported to date was conducted in 100 cancer patients undergoing bone marrow biopsy and aspiration. As methoxyflurane has a characteristic odour, 2e3 drops of methoxyflurane were placed on the outside of the placebo-loaded inhaler before sealing the plastic bag so that the smell of methoxyflurane was present for both active and placebo treatments. Patients using the inhaler experienced significantly less procedural pain, particularly during the more painful aspiration part of the procedure (P<0.001). Methoxyflurane was no better than placebo in reducing anxiety levels measured with the State Trait Anxiety Inventory, however anxiety levels were low preprocedure, making a difference between the two arms difficult to detect. Only one patient, who was in the placebo arm, requested rescue analgesia. 31 Patients and study nurses rated methoxyflurane as preferable to placebo (P¼0.005 and P<0.001, respectively). Grade 1 euphoria was the only adverse event definitely attributable to methoxyflurane. A 30-day follow-up showed no instances of renal or hepatic toxicity associated with the use of methoxyflurane analgesia. The authors concluded that overall, methoxyflurane was a well-tolerated and simple to use adjunct for analgesia for bone marrow patients. Following this trial, methoxyflurane has been incorporated into standard procedure for bone marrow biopsy at this cancer centre.
Prostate biopsy
Transrectal ultrasound (TRUS)-guided biopsy of the prostate is the gold standard technique for the detection of prostate cancer worldwide. It is performed on an outpatient basis under light sedation or local anaesthesia only. However, the procedure can be intensely painful and is associated with considerable patient anxiety. 41, 42 Multiple analgesic modalities have been tried to improve patient comfort, with limited success. 43 Periprostatic infiltration of local analgesia (PILA) is generally accepted as the most effective and therefore minimum standard analgesia for TRUS-guided prostate biopsy, although its efficacy is uncertain. 42 An Australian group examined whether self-administered methoxyflurane via a proprietary inhaler might be a useful analgesic agent for this procedure. 44, 45 In an initial prospective study, these authors trained 42 consecutive patients scheduled for TRUS-guided prostate biopsy in the use of the methoxyflurane inhaler. 44 The inhaler was used as the sole analgesic agent during the procedure and the patients rated their pain on a visual analogue scale (VAS, 0e10). The median pain score was 3, but surprisingly, those patients having a higher number of core samples had a lower median pain score of 2. All patients were satisfied with the technique, and side effects were rare, minor, and self-limiting. In a further prospective study, these authors recruited 72 consecutive patients undergoing TRUS-guided prostate biopsy to receive either methoxyflurane inhaler alone or the inhaler plus a PILA technique. 45 It was hypothesised that as local anaesthetic infiltration is performed after rectal probe insertion, using the inhaler would make probe insertion and injection of local anaesthetic more comfortable for the patient.
Median pain scores were indeed significantly lower in the combined inhaler/PILA group than in those receiving methoxyflurane alone, but all patients in both groups indicated they would be happy to receive their respective analgesic technique in the future. As in their initial study, the authors found that side effects were infrequent, minor, and self-limiting, leading them to conclude that methoxyflurane is a well-tolerated alternative for prostate biopsy. 45 However, another group using similar methodology (a prospective series of 64 consecutive patients undergoing TRUS-guided prostate biopsy), described equivocal results with sole use of a methoxyflurane inhaler. 46 Although median VAS scores were acceptable for each phase of the procedure, less than half of the patients expressed willingness to undergo a similar procedure using a methoxyflurane inhaler in the future. A subgroup of study participants who had had previous biopsies under PILA analgesia expressed a preference for this latter technique, and four patients were unable to tolerate prostate biopsy under methoxyflurane analgesia and had to be converted to a PILA technique. The authors of this study postulate that patient difficulty in managing the inhalation technique, and an intolerance of the 'sickly sweet' taste of the inhaled gas, were contributory factors in failure of the methoxyflurane technique. It can be speculated that the difference between the two studies might be the level of pre-procedure instruction in inhaler use provided to the study patients. A randomised controlled trial of inhaled methoxyflurane vs placebo as an adjunct to PILA for TRUS biopsy is currently under way. In addition to quality of procedural pain relief, this study will investigate the quality of the patient experience of methoxyflurane analgesia. 47 
Burns dressings
Inhaled methoxyflurane was found to be a well-tolerated and effective analgesic technique for the changing of burns dressings quite early in its history, 34 although its use in this setting was not pursued. Frequent redressing of burn wounds is a necessary intervention that can cause considerable pain and anxiety. 35, 48 Patients require long-term pain relief and are often opioid tolerant, making analgesia for short-term procedures more challenging. 48, 49 Opioids such as fentanyl have been used for burns procedures but require i.v. access and may pose problems such as respiratory depression. 50 Recently, a study by Wasiak and colleagues 51 re-confirmed the efficacy of methoxyflurane delivered via self-administered inhalation for the redressing of burns in an outpatient setting. In this study, 15 adult burn patients presenting for outpatient dressing changes were trained to self-administer inhaled methoxyflurane via a proprietary inhaler immediately before the procedure. The patients were asked to rate their experiences of pain and anxiety before and after the change of dressing via a numerical scale (Numerical Pain Rating Scale, 0e10 and Numerical Anxiety Rating Scale, 0e10), and to provide a personal assessment of the efficacy of the methoxyflurane inhaler for this procedure. Although the procedures were relatively long (mean 38 min), all patients tolerated the dressing changes well, with only one individual requiring additional pain relief post-procedure. The majority of patients required only one 3 ml dose of methoxyflurane via an inhaler, with one requiring two doses. The median pain scores post-procedure were higher than pre-procedure levels.
In contrast, anxiety levels were substantially reduced postprocedure, although it could not be determined whether the use of methoxyflurane contributed to this reduction or whether subjects were less anxious because their preprocedure anxiety had dissipated. Only two patients experienced minor, self-limiting side effects, and overall the authors concluded that methoxyflurane delivered via an inhaler was a well-tolerated analgesic for outpatient burns dressing changes. 51 A second study examining the efficacy of inhaled methoxyflurane for burns dressing changes compared this analgesic modality with the ketamine-midazolam infusion combination already in use at the authors' institution for this purpose. 52 A randomised crossover design was used to allocate patients to one of the analgesic regimes on their initial attendance for dressing change, and then the other modality on their second visit. Eight patients completed the crossover design and five of these indicated a preference for the methoxyflurane inhaler, two patients were equally happy with either i.v. sedation or the inhaler, and only one patient preferred the ketamine-midazolam combination. Pain scores were similar between the two techniques. However, patients cited the ability to self-administer the medication and associated sense of control as a positive aspect of methoxyflurane. Hallucinations, sedation, and drowsiness, all of which are common features of ketamine-midazolam sedation, were not experienced with methoxyflurane. There were no reported side effects or adverse events noted with methoxyflurane inhalation. In contrast, the ketamine-midazolam modality induced a sensation of prolonged sedation in two of the patients. 52 These data the data from Wasiak and colleagues 51 suggest that methoxyflurane delivered via a proprietary inhaler is not inferior to other sedative-analgesic techniques for repeat changes of burns dressings and may offer some advantages in terms of reduced sedation and viability in the setting of difficult i.v. access.
Minor general surgical procedures
The authors of the crossover study for burns management also included a prospective audit, carried out after the crossover study, on the use of inhaled methoxyflurane for various minor surgical procedures, including changes of vacuum assisted closure wound dressings, further burns dressings, drainage of abscesses, and a variety of additional general surgical and vascular procedures. 52 Methoxyflurane was utilised as the primary analgesic technique in 123 patients undergoing 173 separate procedures. In general, success rates (i.e. no requirement to use alternative techniques) were high. No incidences of significant oxygen desaturation were noted, and airway support was not required in any of these patients. There were five failures of the technique (out of 173 administrations). Two of these were in patients requiring drainage of anal or perianal abscesses, for whom a full general anaesthetic might have been more appropriate. Two further patients had pre-existing chronic pain conditions and exhibited high anxiety levels, and the fifth patient was elderly and became agitated during an unexpectedly long procedure. In all five reported failures of the technique, therefore, methoxyflurane inhalation failed only in circumstances where most sedativeanalgesic techniques might also fail. The study authors noted that high anxiety levels may prevent some patients from being able to use the hand-held inhaler effectively despite pre-procedure explanation and training.
Additional procedural uses of methoxyflurane
Three studies have examined the efficacy of inhaled methoxyflurane for types of outpatient procedures associated with significant patient discomfort that otherwise might require sedation. 25, 32, 53, 54 Patients undergoing computed tomography enteroclysis for the diagnosis and assessment of small bowel disease require nasal insertion of the endoscope and injection of contrast material into the bowel, which may cause significant discomfort, sometimes requiring i.v. sedation for patient comfort, with the attendant risks of drowsiness and respiratory depression. 54 One study has examined the use of methoxyflurane as an alternative analgesic modality. 53 In this randomised double-blinded comparison against placebo, methoxyflurane significantly reduced patient discomfort during nasal insertion of the endoscope, but did not reduce the discomfort of other parts of the procedure in comparison with placebo. The study was small (60 patients), and adverse events were infrequent and spread equally between active therapy and placebo groups. No serious cardiorespiratory events occurred and overall levels of patient comfort were the same in both groups. Finally, a small study compared inhaled methoxyflurane analgesia against nitrous oxide for dental extraction. 25 Methoxyflurane induced comparable degrees of sedation to nitrous oxide. Patient and dental surgeon satisfaction were similar for both inhalational agents, although methoxyflurane was preferred on grounds of ease of use.
Inhaled methoxyflurane in obstetric practice
Around the time that methoxyflurane anaesthesia was coming under scrutiny, the potent analgesic effects of short-term, lowdose (0.25e0.5%), inhaled methoxyflurane were being examined. Low-dose self-administered methoxyflurane for analgesia in labour was found to give effective analgesia without any adverse effects with labour or foetal Appearance, Pulse, Grimace, Activity, Respiration (APGAR) scores, 36 and in fact was better tolerated than Entonox (50% N 2 O/50% O 2 ) for this purpose. 55 Careful clinical studies demonstrated no renal adverse effects of methoxyflurane delivered in this manner. 56, 57 The use of methoxyflurane as a labour analgesic declined with the increasing popularity of epidural analgesia. However, a very recent study found that labouring women who selfadministered inhaled methoxyflurane during epidural placement experienced less painful contractions and reduced anxiety, and were better able to co-operate with epidural insertion. 26 
Directions for future research
The recent clinical studies discussed in this review indicate that inhaled methoxyflurane is an effective analgesic for outpatient medical procedures. Ease of use, combined with a rapid return to normal activity, offer advantages of cost and convenience over traditional, opioid analgesia. However, whilst the use of methoxyflurane for emergency trauma pain is well-established, large-scale clinical trials are still required to determine the optimum use of methoxyflurane for the newer indication of short-term management of acute pain during out-patient procedures. This section explores potential areas of new research. The design of the commercially available methoxyflurane inhaler (Penthrox ® ) allows for the contents of the 3 ml vial to be administered at a concentration of either 0.2e0.4% or 0.5e0.7%. 5 Strict formal dosing studies are not of specific value, as the benefit of this product is based on this 'self' dosing according to the individual needs, which are in turn influenced by variations in breathing depth and inhaler technique. Dose-ranging studies, in which patients receiving one specific procedural intervention are randomised to receive either the higher or lower concentration of methoxyflurane via the commercial inhaler, might help to reduce variability between the results of future large-scale trials of inhaled methoxyflurane. Further, as healthcare becomes increasingly protocol-driven, evidence-based dosage recommendations for individual procedures will allow nurse-led rather than anaesthetist-led management of pain relief during out-patient procedures, 58 and allow tailoring of specific dosage regimens for different groups of patients. For example, in patients undergoing colonoscopy, the initial randomised controlled trial assessing the efficacy and tolerability of methoxyflurane against traditional opioid/midazolam analgesic techniques showed unequivocal advantages for inhaled methoxyflurane in terms of patient comfort, reduced sedation, and earlier discharge. 23 However, although a subsequent study broadly confirmed these findings in morbidly obese colonoscopy patients, pain scores during the procedure were significantly higher than in patients receiving traditional opioid analgesia. 24 This suggests that patients with a higher body mass index might require a different dosing regimen. The duration of analgesia provided by a single dose of inhaled methoxyflurane is around 25 min, with the actual duration of analgesia determined in large part by the effectiveness of use of the methoxyflurane inhaler determined largely by the depth and frequency of breathing. 59 In the observational study of methoxyflurane for change of burns dressings, the authors reported that for most patients, one 3 ml dose of methoxyflurane was adequate, even though the procedure had a mean duration of action of 38 min, well beyond the accepted duration of action for one vial. 51 Future studies examining optimum dosage of methoxyflurane would provide a more accurate assessment of analgesia effect over time. Studies indicate that methoxyflurane may have an anxiolytic effect in addition to analgesia. It would be of interest to explore the effect of inhaled methoxyflurane in population subgroups with mild to moderate anxiety, where the combination of improved autonomy afforded by the inhaler technique may contribute to the known anxiolytic properties of the methoxyflurane.
Previous studies of methoxyflurane in colonoscopy may offer safety advantages compared with i.v. sedation, for example, less episodes of hypotension or low oxygen saturation. Further research focusing on episodes of hypotension and desaturation with inhaled methoxyflurane as primary end points is needed.
The randomised controlled trial comparing methoxyflurane analgesia with an opioid/midazolam technique for colonoscopy demonstrated significant advantages for methoxyflurane inhalation, including shorter procedure duration, less sedation or respiratory depression, and more rapid discharge. 23 However, there are few published studies which directly compare current analgesic and sedative techniques with methoxyflurane for any out-patient procedure. 59 Such randomised controlled trials would conclusively add to the evidence, although blinding of treatments is somewhat complicated by the very different nature of administration of the different techniques. Another challenge to blinding is when the effects of methoxyflurane in the patient become familiar to the treating physician/nurse, a situation which may lead to bias with the assessment. This could be overcome in future randomised controlled trials by documenting impressions of clinicians as to patient allocation. A possible area of concern in designing clinical trials is the lack of familiarity with the methoxyflurane inhaler itself, either on the part of the patient or the healthcare professional administering the agent. For example, patients taking part in a study using TRUS-guided prostate biopsy had to be educated in the use of the inhaler during the procedure, and the authors considered the possibility that this might have affected the outcome of the study. 46 Although the proprietary inhaler is very familiar to patients and clinicians in some parts of the world, 60 staff training and patient familiarisation would need to be part of the study protocol in countries where introduction of the methoxyflurane inhaler is either recent or anticipated in the near future, in order to reduce variation in study data imposed by errors in administration techniques. So far, the published studies have been too small to determine the cost-saving implications of utilising methoxyflurane as the primary analgesic for out-patient procedures. Although the potential cost benefits of avoiding opiate analgesia in favour of a potent, but short-acting agent which allows earlier discharge might seem obvious, compelling evidence has not yet been gathered. Well-powered studies demonstrating similar clinical efficacy and an improved cost profile are essential to overcome resistance to change which might otherwise impede adoption of the new technique.
Lastly, new studies should explore whether methoxyflurane may be used as an adjunct to other analgesic techniques as part of multimodal pain management. An example might be the brief use of a methoxyflurane inhaler to provide patient comfort during placement of epidural analgesia for labour pain, as described by Anwari and colleagues. 26 Methoxyflurane significantly enhances pain relief in patients undergoing bone marrow biopsy under local analgesia. 31 In a different patient group, the inhalation of methoxyflurane during local anaesthetic infiltration for TRUS-guided prostate biopsy may prove to be more efficacious than either technique alone. 47 
Conclusion
Low-dose methoxyflurane administered via a handheld inhaler has provided well-tolerated short-term pain relief for trauma patients in Australasia for many years. Minor side effects including dizziness, nausea, and disorientation, do occur but are mainly dispelled rapidly, within minutes of cessation of inhaler use. Although high output renal failure was a major complication of methoxyflurane, renal and hepatic toxicity are extremely rare following short duration use at lower concentrations for analgesia. Inhaled methoxyflurane is also approved in Australasia for use as an analgesic agent for outpatient medical and surgical procedures. 
